Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6.

Autor: Hughes BGM; Department of Cancer Care Services, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia; Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia. Electronic address: brett.hughes@health.qld.gov.au., Guminski A; Department of Medical Oncology, Royal North Shore Hospital, St Leonards, New South Wales, Australia., Bowyer S; Department of Medical Oncology, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia., Migden MR; Departments of Dermatology and Head and Neck Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas., Schmults CD; Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts., Khushalani NI; Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, Florida., Chang ALS; Department of Dermatology, Stanford University School of Medicine, Redwood City, California., Grob JJ; Aix Marseille University, Hôpital de la Timone, Marseille, France., Lewis KD; University of Colorado Denver Cancer Center, Aurora, Colorado., Ansstas G; Department of Surgical Oncology, Washington University School of Medicine, St Louis, Missouri., Day F; Department of Medical Oncology, Calvary Mater Newcastle, Newcastle, New South Wales, Australia., Ladwa R; Department of Medical Oncology, Royal North Shore Hospital, St Leonards, New South Wales, Australia; Princess Alexandra Hospital, Woolloongabba, Queensland, Australia., Stein BN; Adelaide Cancer Centre, Adelaide, South Australia, Australia., Muñoz Couselo E; Department of Medical Oncology, Melanoma and Other Skin Tumors Unit, Vall d'Hebron University Hospital, Barcelona, Spain., Meier F; Department of Dermatology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany; Skin Cancer Center at the University Cancer Centre and National Center for Tumor Diseases, Dresden, Germany., Hauschild A; Department of Dermatology, University Hospital (UKSH), Kiel, Germany., Schadendorf D; Department of Dermatology, University Hospital of Essen, Essen, Germany; German Cancer Consortium, Partner Site Essen, NCT-West, Campus Essen and University Alliance Ruhr, Research Center One Health, University Duisburg-Essen, Essen, Germany., Basset-Seguin N; Hôpital Saint-Louis, Paris, France., Modi B; Division of Dermatology, Department of Surgery, City of Hope, Duarte, California., Dalac-Rat S; Hospital Center University Dijon Bourgogne, Dijon, France., Dunn LA; David H. Koch Center for Cancer Care, Memorial Sloan Kettering Cancer Center, New York, New York., Flatz L; University Hospital Tübingen, Tübingen, Germany., Mortier L; Centre Hospitalier Régional Universitaire de Lille (CHRU), Lille, France., Guégan S; Department of Dermatology, Hôpital Cochin, Paris, France., Heinzerling LM; Department of Dermatology, LMU University Hospital Munich, Munich, Germany; Department of Dermatology, University Hospital Erlangen, Erlangen, Germany., Mehnert JM; Melanoma and Cutaneous Medical Oncology, Perlmutter Cancer Center, NY University, Langone Health, New York, New York., Trabelsi S; CHU de Grenoble - Hôpital A Michallon, Grenoble, France., Soria-Rivas A; Ramón y Cajal University Hospital, Spanish Society of Medical Oncology (SEOM), Madrid, Spain., Stratigos AJ; First Department of Dermatology-Venereology, Andreas Sygros Hospital, Athens, Greece; National and Kapodistrian University of Athens Medical School, Athens, Greece., Ulrich C; Charite-Universitatsmedizin Berlin, Berlin, Germany., Wong DJ; UCLA Department of Medicine, Los Angeles, California., Beylot-Barry M; Department of Dermatology, University Hospital of Bordeaux, Bordeaux, France., Bossi P; Department of Biomedical Sciences, Humanitas University, Milan, Italy; IRCCS Humanitas Research Hospital, Milan, Italy., Bugés Sánchez C; Department of Medical Oncology, Skin Tumors Unit, Catalan Institute of Oncology, Germans Trias i Pujol University Hospital, Barcelona, Spain; Badalona-Applied Research Group in Oncology (B-ARGO), Badalona, Barcelona, Spain., Chandra S; Division of Hematology Oncology, Northwestern University Feinberg School of Medicine, Chicago, Illinois., Robert C; Gustave Roussy Cancer Center, Villejuif, France., Russell JS; Head and Neck/Cutaneous Medical Oncology, Huntsman Cancer Institute, Salt Lake City, Utah., Silk AW; Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., Booth J; Regeneron Pharmaceuticals, Inc., Tarrytown, New York., Yoo SY; Regeneron Pharmaceuticals, Inc., Tarrytown, New York., Seebach F; Regeneron Pharmaceuticals, Inc., Tarrytown, New York., Lowy I; Regeneron Pharmaceuticals, Inc., Tarrytown, New York., Fury MG; Regeneron Pharmaceuticals, Inc., Tarrytown, New York., Rischin D; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.

Publikováno v: Journal of the American Academy of Dermatology [J Am Acad Dermatol] 2024 Sep 07. Date of Electronic Publication: 2024 Sep 07.

Spatial dynamics of tertiary lymphoid aggregates in head and neck cancer: insights into immunotherapy response.

Autor: Sadeghirad H; Frazer Institute, Faculty of Medicine, Translational Research Institute, The University of Queensland, 37 Kent Street, Woolloongabba, QLD, 4102, Australia., Monkman J; Frazer Institute, Faculty of Medicine, Translational Research Institute, The University of Queensland, 37 Kent Street, Woolloongabba, QLD, 4102, Australia., Tan CW; Frazer Institute, Faculty of Medicine, Translational Research Institute, The University of Queensland, 37 Kent Street, Woolloongabba, QLD, 4102, Australia.; Bioinformatics Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Melbourne, VIC, 3052, Australia.; Department of Medical Biology, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Parkville, VIC, 3010, Australia., Liu N; Bioinformatics Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Melbourne, VIC, 3052, Australia.; Department of Medical Biology, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Parkville, VIC, 3010, Australia.; South Australian immunoGENomics Cancer Institute, The University of Adelaide, SA, Australia., Yunis J; Frazer Institute, Faculty of Medicine, Translational Research Institute, The University of Queensland, 37 Kent Street, Woolloongabba, QLD, 4102, Australia.; Ian Frazer Centre for Children's Immunotherapy Research, Children's Health Research Centre, Faculty of Medicine, The University of Queensland, South Brisbane, QLD, Australia., Donovan ML; Frazer Institute, Faculty of Medicine, Translational Research Institute, The University of Queensland, 37 Kent Street, Woolloongabba, QLD, 4102, Australia.; Queensland Spatial Biology Centre, Wesley Research Institute, The Wesley Hospital, Auchenflower, QLD, Australia., Moradi A; Frazer Institute, Faculty of Medicine, Translational Research Institute, The University of Queensland, 37 Kent Street, Woolloongabba, QLD, 4102, Australia., Jhaveri N; Discovery Applications, Akoya Biosciences, The Spatial Biology Company, Marlborough, MA, USA., Perry C; The Princess Alexandra Hospital, Woolloongabba, QLD, Australia., Adams MN; Centre for Genomics and Personalised Health, School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, QLD, Australia., O'Byrne K; The Princess Alexandra Hospital, Woolloongabba, QLD, Australia.; Centre for Genomics and Personalised Health, School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, QLD, Australia., Warkiani ME; University of Technology Sydney, NSW, Australia., Ladwa R; Frazer Institute, Faculty of Medicine, Translational Research Institute, The University of Queensland, 37 Kent Street, Woolloongabba, QLD, 4102, Australia.; The Princess Alexandra Hospital, Woolloongabba, QLD, Australia., Hughes BGM; The Royal Brisbane and Women's Hospital, Herston, QLD, Australia.; School of Medicine, University of Queensland, Brisbane, QLD, Australia., Kulasinghe A; Frazer Institute, Faculty of Medicine, Translational Research Institute, The University of Queensland, 37 Kent Street, Woolloongabba, QLD, 4102, Australia. Arutha.kulasinghe@uq.edu.au.; Queensland Spatial Biology Centre, Wesley Research Institute, The Wesley Hospital, Auchenflower, QLD, Australia. Arutha.kulasinghe@uq.edu.au.

Publikováno v: Journal of translational medicine [J Transl Med] 2024 Jul 24; Vol. 22 (1), pp. 677. Date of Electronic Publication: 2024 Jul 24.

Capmatinib plus nivolumab in pretreated patients with EGFR wild-type advanced non-small cell lung cancer.

Autor: Felip E; Medical Oncology Service, Vall d'Hebron Institute of Oncology, Vall d'Hebron Barcelona Hospital Campus, Universitat Autonoma de Barcelona, Spain. Electronic address: efelip@vhio.net., Metro G; Medical Oncology, Santa Maria della Misericordia Hospital, Azienda Ospedaliero-Universitaria di Perugia, Perugia, Italy., Tan DSW; National Cancer Center Singapore, Singapore., Wolf J; Department of Internal Medicine, Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany., Mark M; Division of Oncology/Hematology, Kantonsspital Graubuenden, Chur, Switzerland; Università della Svizzera Italiana, Lugano, Switzerland., Boyer M; Department of Oncology, Chris O'Brien Lifehouse, New South Wales, Australia., Hughes BGM; The Prince Charles Hospital and University of Queensland, Queensland, Australia., Bearz A; Centro di Riferimento Oncologico-IRCCS, Aviano, Italy., Moro-Sibilot D; Thoracic Oncology, CHU Grenoble-Alpes, Grenoble, France., Le X; The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Puente J; Medical Oncology Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), CIBERONC, Madrid, Spain., Massuti B; Alicante University Hospital, Alicante, Spain., Tiedt R; Novartis Pharma AG, Basel, Switzerland., Wang Y; Novartis Institutes for Biomedical Research Co., Ltd, Shanghai, China., Xu C; Novartis Institutes for Biomedical Research Co., Ltd, Shanghai, China., Mardjuadi FI; Novartis Institutes for Biomedical Research Co., Ltd, Shanghai, China., Cobo M; Medical Oncology Intercenter Unit. Regional and Virgen de la Victoria University Hospitals, IBIMA, Málaga, Spain.

Publikováno v: Lung cancer (Amsterdam, Netherlands) [Lung Cancer] 2024 Jun; Vol. 192, pp. 107820. Date of Electronic Publication: 2024 May 10.